By James Waldron
New long-term data from Takeda’s TIDES study of its dengue fever vaccine provide the missing piece of the puzzle in the Japanese pharma’s quest to bring the first travel shot for the infection to market.
read more
By Andrea Park
Tempus fugit, but the Chicago medtech of the same name is aiming to stop the clock on cancer with its genomic sequencing tests.
read more
By Dave Muoio
Northside Hospital Atlanta and Northside Hospital Cherokee ignored CMS' warnings and requests for corrective action since last fall, the agency said. They now face hundreds of thousands of dollars in fines.
read more
By Angus Liu
AbbVie’s megablockbuster TNF blocker Humira is about to face biosimilars next year. But will those biosims succeed? According to analysts who examined Viatris and Biocon’s two biosimilar versions of Sanofi’s popular insulin Lantus, both high- and low-list-priced Humira copycats actually could steal market share.
read more
By Dave Muoio
The bipartisan legislation is modeled after similar protections for airline workers and is backed by the American Hospital Association and American College of Emergency Physicians.
read more
By Max Bayer
Alnylam has reached a phase 2 checkpoint of its Regeneron-partnered immunoglobulin A nephropathy treatment as it looks to catch up with Calliditas Therapeutics' FDA-approved med Tarpeyo.
read more
By Ben Adams
As GlaxoSmithKline becomes GSK and sheds its consumer unit, the British Big Pharma has revealed new branding, a tech-flavored logo and a “transformative” change for its future.
read more
By Conor Hale
For the first time, Abbott showed that its transcatheter clip-based therapy for the heart’s tricuspid valve could help stem leaks and improve quality of life specifically among patients who have received a pacemaker implant.
read more
By Nick Paul Taylor
CureVac, bruised from its COVID-19 vaccine woes, has struck another deal to bolster its cancer vaccine development capabilities, buying Frame Cancer Therapeutics for its ability to identify unique and shared neoantigens.
read more
By Andrea Park
Foundation Medicine’s flagship cancer diagnostic is designed to detect substitutions and alterations in more than 300 genes—and the company seemingly won’t rest until the test has been cleared for use alongside just as many cancer drugs.
read more
By Gabrielle Masson
Takeda Oncology employees arrived on the scene at the American Society of Clinical Oncology meeting eager to be back in person and ready to talk potential partnerships that could bolster the Japanese pharma's three main “pillar” areas.
read more
By Paige Minemyer
The United Health Foundation, the philanthropic arm of UnitedHealth Group, will invest $100 million over the next decade to drive a more diverse healthcare workforce.
read more
